Evommune, Inc. (EVMN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Evommune reported revenue of $13.0M. Net income was -$68.9M (a -529.8% net margin), or -$11.22 per diluted share. Operating margin was -623.6%. Operating activities generated -$76.4M of cash, leaving -$76.7M of free cash flow. At fiscal year end, Evommune held $224.9M in total assets against $19.4M in total liabilities, including $44.1M of cash and equivalents.
Open the full interactive Evommune financials → Quarterly statements, key ratios, valuation history and price charts.
Evommune Key Stats
| Share Price | $5.88 |
|---|---|
| Market Cap | $212.5M |
| 52-Week Range | $5.88 – $31.57 |
| Shares Outstanding | 36.1 million (basic, 2026 Q2) |
Evommune Income Statement
| FY 2025 | |
|---|---|
| Revenue | $13.0M |
| Operating Income | -$81.1M |
| Pre-Tax Income | -$68.9M |
| Income Tax | $0 |
| Net Income | -$68.9M |
| Diluted EPS | -$11.22 |
Evommune Quarterly Results
| 2025 Q3 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|
| Revenue | $10.0M | $0 | $0 |
| Net Income | -$12.5M | -$21.7M | -$32.2M |
| Diluted EPS | -$8.07 | -$0.64 | -$0.89 |
Evommune Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $44.1M |
| Current Assets | $153.5M |
| Total Assets | $224.9M |
| Current Liabilities | $17.9M |
| Total Liabilities | $19.4M |
| Shareholders' Equity | $205.6M |
Evommune Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$76.4M |
| Cash From Investing | -$115.3M |
| Cash From Financing | $220.8M |
| Free Cash Flow | -$76.7M |
Figures from Evommune's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Evommune financials page for every line item.
Evommune Company Profile
| Ticker | EVMN |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Palo Alto, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002044725 |
Frequently Asked Questions
What was Evommune's revenue in fiscal 2025?
Evommune (EVMN) reported revenue of $13.0M for fiscal 2025.
What was Evommune's net income in fiscal 2025?
Evommune reported net income of -$68.9M for fiscal 2025.
What was Evommune's earnings per share (EPS) in fiscal 2025?
Evommune's diluted EPS was -$11.22 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Evommune generate in fiscal 2025?
Evommune generated -$76.7M of free cash flow in fiscal 2025.
What was Evommune's revenue last quarter?
In its most recent reported quarter (2026 Q2), Evommune reported revenue of $0.
How many shares of Evommune are outstanding?
Evommune reported a weighted average of 36.1 million basic shares outstanding in 2026 Q2.
What is Evommune's market cap?
Based on its latest closing price, Evommune (EVMN) has a market capitalization of about $212.5M.
When does Evommune's fiscal year end?
Evommune's fiscal year end, as registered with the SEC, is December 31.
Where is Evommune headquartered?
Evommune lists its business address in Palo Alto, California in its SEC filings.